The largest study to date looking at whether the risk of bone fractures is increased in the setting of thiazolidinedione drugs (TZDs) suggests that fracture risk is more than 40% higher in people taking TZDs and that both men and women are vulnerable
Read More »HCTZ Not a Drug of Choice for Treating Hypertension
Hydrochlorothiazide (HCTZ), the most commonly employed blood-pressure-lowering drug in the US, used at the usual doses prescribed—12.5 mg to 25 mg/per day—is a “paltry” antihypertensive, inferior to all other drug classes, and there is no published evidence that it reduces heart attack or stroke.
Read More »Nicotine Increases Risk of Diabetes and Prediabetes
Nicotine increases cortisol levels, encourages insulin resistance, study finds.
Read More »Cornflakes, White Bread Boost Heart Risk
Eating a diet rich in carbohydrates that boost blood sugar levels — foods such as cornflakes or white bread — may hamper the functioning of your blood vessels and raise your risk of developing cardiovascular disease, a new study suggests.
Read More »Wide Disparity Found in Drug Prices for Diabetes Patients
New research from Mount Sinai School of Medicine has found that the price in New York and New Jersey of the medications most commonly prescribed for patients with diabetes varies widely depending on where you shop.
Read More »Snoring Pregnant Women at Higher Risk for Gestational Diabetes
If you are pregnant and your mate complains your frequent snoring is rattling the bedroom windows, you may have bigger problems than an annoyed, sleep-deprived partner
Read More »ADA – Diabetes Associated with Hearing Loss
Diabetic patients with poor glycemic control or vascular or neuropathic complications may also suffer from hearing loss. All patients with hemoglobin A1c levels greater than 7% had hearing impairment.
Read More »ADA – Saxagliptin Lowers Glucose, Reduces Cardiovascular Events
Saxagliptin, an investigational dipeptidyl peptidase-4 (DPP4) inhibitor, may offer cardioprevention as a side benefit of diabetes treatment, according to a meta-analysis.
Read More »ADA – New Dual PPAR Agonist Promising for Diabetes
Aleglitazar, a novel dual peroxisome proliferator-activated receptor (PPAR) agonist, is effective for glucose control in Type 2 diabetes and reduces A1c 1.3%.
Read More »Glucose Metabolism can Forecast Diabetes Five Years Ahead
Insulin sensitivity, beta-cell function, and blood glucose may provide telltale signs of impending Type 2 diabetes up to five years before onset, researchers affirmed.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.